Evidence
J Gastrointestin Liver Dis. 2024 Mar 29;33(1):7-10. doi: 10.15403/jgld-5268.
ABSTRACT
Patients with chronic liver diseases (CLD) were considered to be in peril during the initial stages of the Coronavirus disease (Covid-19) pandemic. Progression of the course of the pandemic, however indicated that risk of severe disease and mortality differed, based on the cause of the hepatic disease. Patients suffering from Alcoholic liver disease or liver cirrhosis were confirmed to be at an increased risk by numerous studies, while that was not the case for HBV affected individuals and liver transplant recipients. The grade of liver fibrosis seemed to be the decisive factor for the severity of Covid-19 infection in the case of HCV infected individuals. Results are conflicting in the case of patients with metabolic- associated steatotic liver disease (MASLD) and insufficient in those with autoimmune liver disease.
PMID:38554411 | DOI:10.15403/jgld-5268
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
COVID-19 in Individuals with Chronic Liver Diseases
🌐 90 Days
VR Related Evidence Matrix
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Occult liver disease: a multinational perspective
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- Inflammatory liver diseases and susceptibility to sepsis
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Liver cirrhosis in a patient with alcohol dependence and autoimmune hepatitis
- The double roles of T cell-mediated immune response in the progression of MASLD
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Apathetic Graves' disease with severe hepatic and renal dysfunction induced by COVID-19 infection: Case report and literature review
- The gut-liver axis in fatty liver disease: role played by natural products
- Spatial genomics: mapping human steatotic liver disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead
- The pleiotropic approach to coronavirus disease-19 pathogenesis: The impact of liver diseases associated host genetic variants
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Time trends in liver-related mortality in people with and without diabetes: Results from a population based study
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- The role of sirtuin1 in liver injury: molecular mechanisms and novel therapeutic target
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage
- Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry
- A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry
- Interleukins in liver disease treatment
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Emerging roles of RNA-binding proteins in fatty liver disease
- Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study
- Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
Evidence Blueprint
COVID-19 in Individuals with Chronic Liver Diseases
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
COVID-19 in Individuals with Chronic Liver Diseases
🌐 365 Days
VR Related Evidence Matrix
- Influence of chronic liver diseases on the course and outcome of COVID-19
- Mortality from chronic liver disease: Recent trends and impact of the COVID-19 pandemic
- COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Sarcopenia in chronic liver diseases
- Occult liver disease: a multinational perspective
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection
- Therapeutic potential of oleanolic acid in liver diseases
- Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Unconjugated hyperbilirubinemia may exacerbate certain underlying chronic liver diseases
- COVID-19-induced liver injury in infants, children, and adolescents
- Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Gut Mycobiota Changes in Liver Diseases: a Systematic Review
- Impacts of gut microbiota alteration on age-related chronic liver diseases
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- Inflammatory liver diseases and susceptibility to sepsis
- Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: a multi-center, retrospective study
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?
- Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation
- Hormone action and liver disease, a complex interplay
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
- Corrected and republished from: Metabolic associated liver disease
- Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk
- Mitochondrial dysfunction: A promising therapeutic target for liver diseases
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- How non-alcoholic fatty liver disease and cirrhosis affect the heart
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Alcoholic liver disease - 2023
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Liver cirrhosis in a patient with alcohol dependence and autoimmune hepatitis
- Fatty liver and celiac disease: Why worry?
- Portal vein congestion index in patients with and without chronic liver disease
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease
- Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- The double roles of T cell-mediated immune response in the progression of MASLD
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study